Used in immunotherapy for cancer treatment, particularly in targeting the PD-1/PD-L1 pathway to enhance the body's immune response against tumor cells. It blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby preventing immune suppression by the tumor microenvironment. This antibody is investigated in clinical trials for various solid tumors, including non-small cell lung cancer, melanoma, and renal cell carcinoma, aiming to improve durable responses and overall survival. Its high specificity makes it a valuable tool in developing precision medicine approaches in oncology.